Table II.

Anti-CD48 mAb limits histologic EAE

Treatment:	cIgG	anti-CD48
Number of lesions in brain
Parenchyma	39.8 ± 14.2	2.4 ± 1.0 *
Meninges	41.6 ± 9.1	2.8 ± 1.1 **
Number of lesions in spinal cord
Parenchyma	80.4 ± 18.9	0 ± 0 **
Meninges	89.9 ± 14.0	0.8 ± 0.5 ***
Clinical incidence	5/5	0/5 **
Day of onset	13.4 ± 0.2	NA
Maximum clinical score	2	NA

WT mice were immunized for EAE as described, and treated with cIgG or anti-CD48 on days 6, 9 and 12 after immunization. Mice were sacrificed on day 15, and brain and spinal cord were collected for histology. Data are mean ±SEM, except clinical score is median. NA, not applicable.

^*p<0.05

^**p<0.01

^***p<0.001.